(Q34641564)

3 August 2017

1 reference

title

Homocysteine and cardiovascular disease: current evidence and future prospects (English)

1 reference

3 August 2017

cardiovascular disease

1 reference

Arduino A Mangoni

1

1 reference

ORCID Public Data File 2021

author name string

Stephen H D Jackson

series ordinal

2

1 reference

PubMed ID

12015248

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

American Journal of Medicine

3 August 2017

1 reference

3 August 2017

112

1 reference

3 August 2017

7

1 reference

3 August 2017

556-565

1 reference

Emerging noninvasive biochemical measures to predict cardiovascular risk

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia: an independent risk factor for vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Biochemical evidence for a link between elevated levels of homocysteine and lipid peroxidation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Association between elevated plasma total homocysteine and increased common carotid artery wall thickness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma Homocysteine, Aortic Stiffness, and Renal Function in Hypertensive Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteinemia due to folate deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Prevalence of familial mild hyperhomocysteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Thermolabile methylenetetrahydrofolate reductase in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Serum total homocysteine and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and risk of cardiovascular disease among postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and major coronary events: a prospective population study amongst women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

A prospective study of plasma homocyst(e)ine and risk of ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Homozygosity for the C677-->T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocyst(e) ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Effect of hyperparathyroidism on cardiac function in patients with end-stage renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasma endothelin levels in patients with uraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Effect of homocysteine on carotid intima-media thickness after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Vascular and blood pressure effects of folic acid in older patients with cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Fruit and vegetables, and cardiovascular disease: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Treatment of mild hyperhomocysteinemia in vascular disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Plasmatic homocysteine response to vitamin supplementation in elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

Population variation and genetics of plasma homocyst(e)ine level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901021-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(02)01021-5

1 reference

3 August 2017

1 reference

PubMed ID

12015248